Distribution of high and low risk HPV types by cytological status: a population based study from Italy
-
Published:2011-01-20
Issue:1
Volume:6
Page:
-
ISSN:1750-9378
-
Container-title:Infectious Agents and Cancer
-
language:en
-
Short-container-title:Infect Agents Cancer
Author:
Giorgi Rossi Paolo,Chini Francesco,Bisanzi Simonetta,Burroni Elena,Carillo Giuseppe,Lattanzi Amedeo,Angeloni Claudio,Scalisi Aurora,Macis Rosalba,Pini Maria T,Capparucci Paola,Guasticchi Gabriella,Carozzi Francesca M,
Abstract
Abstract
Background
HPV type distribution by cytological status represents useful information to predict the impact of mass vaccination on screening programs.
Methods
women aged from 25 to 64 who attended cervical cancer screening in five different Italian regions were tested for HPV infection with Hybrid Capture II (HCII) low and high risk probes. Women repeating Pap-test upon unsatisfactory or positive results, or as a post-treatment and post-colposcopy follow-up analysis, were excluded from our study. High risk (HR) HPV positive samples were typed using GP5+/GP6+ primed PCR, followed by Reverse Line Blot for 18 high/intermediate risk HPV types, while low risk (LR) HPV positive samples were tested with type specific primers for HPV6 and HPV11.
Results
3410 women had a valid HCII and Pap-test. The prevalence of HR and LR infections was 7.0% and 3.6%, 29.1% and 13.7%, 68.1% and 31.9%, 60.0% and 0.0%, 65.0% and 12.0%, for negative, ASC-US, L-SIL, ASC-H and H-SIL cytology, respectively. The fraction of ASC-US+ cytology due to HPV 16 and 18 ranged from 11.2 (HPV 16/18 alone) to 15.4% (including HPV 16/18 in co-infection with other virus strains), and that due to HPV 6 and 11 ranged from 0.2% (HPV 6/11 alone) to 0.7% (including HPV 6/11 in co-infection with other LR virus strains).
Conclusions
mass vaccination with bivalent or quadrivalent HPV vaccine would modestly impact on prevalence of abnormal Pap-test in screening.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Infectious Diseases,Oncology,Epidemiology
Reference32 articles.
1. Intesa del 20 dicembre 2007 tra il Ministero della Salute, le Regioni e le Province Autonome di Trento e Bolzano, "Strategia per l'offerta attiva del vaccino contro l'infezione da HPV in Italia". 2. Giambi C, De Santis S, (Ed): Workshop. La prevenzione dell'infezione da papilloma virus umano in Italia. (Rapporti ISTISAN 10/25) Roma, 28 settembre 2009. 2010, Atti. Roma: Istituto Superiore di Sanità 3. Giorgi Rossi P, Bisanzi S, Paganini I, Di Iasi A, Angeloni C, Scalisi A, Macis R, Pini MT, Chini F, Carozzi FM, HPV prevalence Italian Working Group: Prevalence of HPV high and low risk types in cervical samples from the Italian general population: a population based study. BMC Infectious Diseases. 2010, 10: 214- 4. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T, Young N, Forum Group Members; Bethesda 2001 Workshop: The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002, 287 (16): 2114-9. 10.1001/jama.287.16.2114. 5. Ronco G, Montanari G, Confortini M, Parisio F, Berardengo E, Delpiano AM, Arnaud S, Campione D, Baldini D, Poll P, Lynge E, Mancini E, Segnan N: Effect of circulation and discussion of cervical smears on agreement between laboratories. Cytopathology. 2003, 14 (3): 115-20. 10.1046/j.1365-2303.2003.00035.x.
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|